• English
  • 中文繁体
  • 中文简体
Hi,
moomoo ID:NaN
Log Out
donwloadimg

Download App

Log in to access Online Inquiry
Quotes
Detailed Quotes
Company Overview
Company ProfileCompany Executives
Financial Analysis
Main CompositionKey IndicatorsFinancial Statement
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 00399 INNOVATIVE PHAR > Financial Statement > Income statement
00399 INNOVATIVE PHAR
0.199
+0.016+8.74%
Income statement Balance sheet Cash flow
YOY
Do not show
Hide blank lines
(FY)2022/03/31(Q6)2021/09/30(FY)2021/03/31(Q6)2020/09/30
Turnover
-26.62% 11.15M -7.27% 6.63M 4.18% 15.19M -35.72% 7.15M
Operating income
-26.62% 11.15M -7.27% 6.63M 4.18% 15.19M -35.72% 7.15M
Cost of sales
26.79% -10.09M 7.77% -5.89M -6.36% -13.78M 36.6% -6.39M
Operating expenses
26.79% -10.09M 7.77% -5.89M -6.36% -13.78M 36.6% -6.39M
Gross profit
-24.98% 1.05M -3.14% 741K -13.27% 1.41M -27.28% 765K
Selling expenses
-- -- 32.79% -82K -- -- 10.29% -122K
Administrative expenses
-1.98% -17.24M -14.39% -8.86M 25.32% -16.91M 39.26% -7.74M
Research and development expenses
-35.36% -8.25M -- -6.52M 46.26% -6.09M -- --
Special items of operating profit
52815.19% 250.82M 113318.1% 250.65M 100.96% 474K 100.73% 221K
Operating profit
1171.73% 226.38M 3530.33% 235.94M 74.16% -21.12M 83.61% -6.88M
Financing cost
0.57% -189.95M -31.49% -114.83M -29.92% -191.03M -15.44% -87.33M
Earning before tax
117.17% 36.43M 228.56% 121.11M 4.63% -212.16M 15.35% -94.21M
After-tax profit from continuing operations
117.17% 36.43M 228.56% 121.11M 4.63% -212.16M 15.35% -94.21M
Earning after tax
117.17% 36.43M 228.56% 121.11M 4.63% -212.16M 15.35% -94.21M
Minority profit
-29.88% -9.37M -423.09% -3.97M 36.39% -7.22M 7.22% -758K
Profit attributable to shareholders
122.35% 45.8M 233.84% 125.08M 2.93% -204.94M 15.41% -93.45M
Basic earnings per share
122.36% 0.0313 233.86% 0.0854 2.91% -0.14 15.5% -0.0638
Diluted earnings per share
122.36% 0.0313 233.86% 0.0854 2.91% -0.14 15.5% -0.0638
Currency Unit
HKDHKDHKDHKD
Accounting Standards
HKASHKASHKASHKAS
Audit Opinions
Unaudited opinion--Qualified opinion--
Auditor
Kaiyuan Xinde accounting firm co., Ltd.--Kaiyuan Xinde accounting firm co., Ltd.--

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report，MOM=(current period - last period)/last period *100%

Company Overview More
Pilot Pharmaceutical and Biotechnology Co., Ltd. is a Hong Kong investment holding company mainly engaged in pharmaceutical and biotechnology business. The company operates through five major divisions. The genetic testing Services Division provides genetic testing services in China and Hong Kong. Bio-industry products division distributes bio-industry products in China. Beauty equipment and products Trading Division is engaged in the trade of beauty equipment and products in Hong Kong, China. The securities investment division engages in securities investment in Hong Kong, China and outside Hong Kong, China. The R & D division is engaged in the R & D and commercialization of oral insulin products.
CEO： Nian Jiang
Market： Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...